Published in J Thorac Oncol on September 01, 2011
Incorporating auxiliary information for improved prediction in high-dimensional datasets: an ensemble of shrinkage approaches. Biostatistics (2012) 1.14
Characterization of vitamin D receptor (VDR) in lung adenocarcinoma. Lung Cancer (2012) 0.91
Epithelial-mesenchymal transition-associated secretory phenotype predicts survival in lung cancer patients. Carcinogenesis (2014) 0.84
BAYESIAN SHRINKAGE METHODS FOR PARTIALLY OBSERVED DATA WITH MANY PREDICTORS. Ann Appl Stat (2013) 0.83
Using machine learning to examine medication adherence thresholds and risk of hospitalization. Med Care (2015) 0.78
Incorporating auxiliary information for improved prediction using combination of kernel machines. Stat Methodol (2015) 0.78
C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma. World J Clin Oncol (2014) 0.78
Metformin and Not Diabetes Influences the Survival of Resected Early Stage NSCLC Patients. J Cancer Sci Ther (2014) 0.75
Data-adaptive Shrinkage via the Hyperpenalized EM Algorithm. Stat Biosci (2015) 0.75
A comparison of the conditional inference survival forest model to random survival forests based on a simulation study as well as on two applications with time-to-event data. BMC Med Res Methodol (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A (2001) 24.34
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A (2001) 17.36
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med (2004) 12.73
A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med (2007) 10.47
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst (2007) 7.44
Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A (2006) 6.26
Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst (2010) 4.80
Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol (2010) 4.19
Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res (2006) 4.11
Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res (2002) 3.68
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol (2009) 3.57
A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med (2006) 3.37
MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res (2009) 3.05
Expression profiling--best practices for data generation and interpretation in clinical trials. Nat Rev Genet (2004) 2.91
Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci U S A (2009) 2.84
Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res (2008) 2.31
Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol (2007) 2.10
An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res (2009) 2.03
Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol (2004) 1.89
Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A (2003) 1.86
Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res (2007) 1.80
Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol (2008) 1.72
Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J Clin Oncol (2008) 1.69
Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res (2002) 1.67
Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res (2008) 1.62
Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma. Clin Cancer Res (2006) 1.55
Expression profiling defines a recurrence signature in lung squamous cell carcinoma. Carcinogenesis (2006) 1.53
A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res (2008) 1.43
Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest (2007) 1.41
Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene (2004) 1.41
Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. Cancer Res (2007) 1.26
Pathway analysis using random forests with bivariate node-split for survival outcomes. Bioinformatics (2009) 1.04
Prognostic gene expression signature for squamous cell carcinoma of lung. Clin Cancer Res (2010) 0.86
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol (2008) 5.46
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (2008) 5.22
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics (2002) 4.56
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res (2006) 4.11
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res (2002) 3.62
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol (2008) 3.55
Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling. Biometrics (2011) 3.38
Subgroup identification from randomized clinical trial data. Stat Med (2011) 3.22
Criteria for the use of omics-based predictors in clinical trials. Nature (2013) 3.15
MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res (2009) 3.05
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 3.03
Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer (2008) 2.98
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst (2010) 2.79
International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG). Ann Surg (2015) 2.61
Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw (2013) 2.56
Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg (2007) 2.48
Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther (2009) 2.47
Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol (2004) 2.42
Non-small cell lung cancer. J Natl Compr Canc Netw (2012) 2.40
Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach. Biostatistics (2009) 2.38
Targeted imaging of esophageal neoplasia with a fluorescently labeled peptide: first-in-human results. Sci Transl Med (2013) 2.30
Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res (2012) 2.26
Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol (2007) 2.20
Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene (2005) 2.07
Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer (2008) 2.06
Semiparametric modeling of longitudinal measurements and time-to-event data--a two-stage regression calibration approach. Biometrics (2008) 2.05
Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res (2009) 2.03
Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw (2011) 2.03
Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res (2011) 2.03
KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma. J Thorac Oncol (2014) 1.99
Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. BMC Bioinformatics (2005) 1.96
Affinity peptide for targeted detection of dysplasia in Barrett's esophagus. Gastroenterology (2010) 1.93
Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol (2003) 1.92
Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol (2013) 1.92
Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A (2003) 1.86
Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Med (2013) 1.84
Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol (2003) 1.83
Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med (2013) 1.79
Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol (2003) 1.74
Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw (2014) 1.71
A bayesian approach to surrogacy assessment using principal stratification in clinical trials. Biometrics (2009) 1.69
Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res (2002) 1.67
RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res (2002) 1.67
On the detection and refinement of transcription factor binding sites using ChIP-Seq data. Nucleic Acids Res (2010) 1.67
Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts. Int J Radiat Oncol Biol Phys (2008) 1.63
Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin. J Natl Cancer Inst (2003) 1.63
Outcomes after transhiatal and transthoracic esophagectomy for cancer. Ann Thorac Surg (2008) 1.62
Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. Clin Cancer Res (2003) 1.62
The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer Res (2002) 1.60
A measure of the proportion of treatment effect explained by a surrogate marker. Biometrics (2002) 1.59
Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res (2003) 1.59
A histologically defined subset of high-grade dysplasia in Barrett mucosa is predictive of associated carcinoma. Am J Clin Pathol (2009) 1.59
Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer. J Thorac Oncol (2014) 1.58
Doubly penalized buckley-james method for survival data with high-dimensional covariates. Biometrics (2007) 1.55
A semi-parametric accelerated failure time cure model. Stat Med (2002) 1.53
Survival analysis using auxiliary variables via non-parametric multiple imputation. Stat Med (2006) 1.53
"Back to the future": recruiting the best and brightest into cardiothoracic surgery. J Thorac Cardiovasc Surg (2010) 1.53
Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw (2015) 1.52
The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys (2006) 1.52
Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer (2005) 1.52
Specialty training and mortality after esophageal cancer resection. Ann Thorac Surg (2005) 1.51
Management of congenital and acquired pulmonary vein stenosis. Ann Thorac Surg (2006) 1.50
Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res (2008) 1.49